Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: A randomized clinical trial

AIDS Patient Care and STDs

Volumn 27, Issue 3, 2013, Pages 146-154

  Dabaghzadeh, Fatemeh ^a,b   Ghaeli, Padideh ^a,c   Khalili, Hossein ^a   Alimadadi, Abbas ^c   Jafari, Sirous ^d   Akhondzadeh, Shahin ^c   Khazaeipour, Zahra ^e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROHEPTADINE; EFAVIRENZ;

ADULT; AGED; AGGRESSION; ANXIETY DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HALLUCINATION; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MALE; MENTAL DISEASE; PITTSBURGH SLEEP QUALITY INDEX; POSITIVE AND NEGATIVE SUICIDE IDEATION; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL INTERCOURSE; SIDE EFFECT; SLEEP QUALITY; SOCIAL AVOIDANCE BEHAVIOR; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TREATMENT DURATION;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CENTRAL NERVOUS SYSTEM DISEASES; CYPROHEPTADINE; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; IRAN; MALE; MENTAL DISORDERS; PERSONALITY INVENTORY; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; SEROTONIN ANTAGONISTS; SOCIOECONOMIC FACTORS; SUICIDAL IDEATION; TREATMENT OUTCOME;

EID: 84875170607     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2012.0410     Document Type: Article

References (63)

1. Bartlett JA, Ferrando SJ. Identification and management of neurologic and psychiatric side effects associated with HIV and HAART. http://www.medscape. com/viewprogram/ 2960-pnt. Accessed February 26, 2010
2. Boyle B, Goldenberg D. Current issues in antiretroviral and psychiatric therapy for HIV-infected patients. AIDS Read 2000;10:508-513
3. Sütterlin S, Vö gele C, Gauggel S. Neuropsychiatric complications of efavirenz therapy: Suggestions for a new research paradigm. J Neuropsychiatry Clin Neurosci 2010;22:361
4. Blanch J, Marti'nez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr 2001;27: 336-343 (Pubitemid 32729079)
5. Gutie'rrez-Valencia A, Viciana P, et al. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: A randomized trial. Ann Intern Med 2009;151: 149-156
6. Puzantian T. Central nervous system adverse effects with efavirenz: Case report and review. Pharmacotherapy 2002; 22:930-933 (Pubitemid 34743443)
7. Rihs T, Begley K, Smith D, et al. Efavirenz and chronic neuropsychiatric symptoms: A cross-sectional case control study. HIV Med 2006;7:544-548 (Pubitemid 44742355)
8. Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav 2011;15:1803
9. Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Neuropsychiatric symptoms associated with efavirenz: Prevalence, correlates, and management. A neurobehavioral review. AIDS Rev 2009;11:103-109
10. Peyriere H, Mauboussin JM, Rouanet I, Fabre J, Reynes J, Hillaire-Buys D. Management of sudden psychiatric disorders related to efavirenz. AIDS 2001;15:1323-324 (Pubitemid 32592372)
11. Bernard EJ. Does efavirenz cause depressioñAIDS Treat Update 2006;158:3
12. Sabato S, Wesselingh S, Fuller A, Ray J, Mijch A. Efavirenzinduced catatonia. AIDS 2002;16:1841-1842
13. Von Giesen HJ, Koller H, de Nocker D, Haslinger BA, Arendt G. Long-term safety and efficacy of NNRTI within the central nervous system. HIV Clin Trials 2003;4:382-390 (Pubitemid 37483590)
14. Treisman GJ, Kaplin AI. Neurologic and psychiatric complications of antiretroviral agents. AIDS 2002;16:1201-1215 (Pubitemid 34666654)
15. Thompson A, Silverman B, Dzeng L, Treisman G. Psychotropic medications and HIV. Clin Infect Dis 2006;42:1305-1310
16. Turjanski N, Lloyd GG. Psychiatric side-effects of medications: Recent developments. Adv Psychiatr Treat 2005;11: 58-70 (Pubitemid 40081381)
17. Goudie AJ, Cooper GD, Cole JC, Sumnall HR. Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats. J Psychopharmacol 2007; 21:179-190 (Pubitemid 46280470)
18. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083-1152 (Pubitemid 29292403)
19. Koek W, Jackson A, Colpaert FC. Behavioral pharmacology of antagonists at 5-HT2/5-HT1C receptors. Neurosci Biobehav Rev 1992;16:95-105
20. Bourgeois J, Bourgeois JA, Hales RE, Young JS. The American Psychiatric Publishing board review guide for psychiatry: Amer Psychiatric Pub Incorporated, Washington, DC, 2009, p. 442
21. Drug Interaction Facts.Tatro DS, editor. Wolters Kluwer Health, Inc., 2012
22. Harsch HH. Cyproheptadine for recurrent nightmares. Am J Psychiatry 1986;143:1491-1492
23. Brophy MH. Cyproheptadine for combat nightmares in post-traumatic stress disorder and dream anxiety disorder. Mil Med 1991;156:100-101
24. Rijnders RJ, Laman DM, Van Diujn H. Cyproheptadine for posttraumatic nightmares. AM J Psychiatry 2000;157:1524
25. Yonker ME. Pharmacologic treatment of migraine. Curr Pain Headache Rep 2006;10:377-381 (Pubitemid 44468633)
26. Stark RJ, Stark CD. Migraine prophylaxis. Med J Aust 2008;189:283-288
27. Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C. Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci 2007;103:201-206 (Pubitemid 46294652)
28. Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol 2004;14:65-73 (Pubitemid 38525955)
29. Koethe JR, Heimburger DC. Nutritional aspects of HIV-associated wasting in sub-Saharan Africa. Am J Clin Nutr 2010;91:1138S-1142S.
30. Polsky B, Kotler D, Steinhart C. HIV-associated wasting in the HAART era: Guidelines for assessment, diagnosis, and treatment. AIDS Patient Care STDs 2001;15:411-423 (Pubitemid 32762700)
31. From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;18:1-19
32. Shams J, Gudarzi SSP, Ghorbani B, Habibi LK, Yasami MT. The efficacy and safety of add-on ginko TD (Ginkgo biloba) treatment for PTSD: Results of a 12-week double-blind placebo- controlled study. Iran J Psychiatry 2007;2:58-64
33. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
34. Bruss GS, Gruenberg AM, Goldstein RD, Barber JP. Hamilton Anxiety Rating Scale Interview guide: Joint interview and test-retest methods for interrater reliability. Psychiatry Res 1994;53:191-202 (Pubitemid 24289076)
35. Malakouti SK, Nojomi M, Panaghi L, et al. Case-management for patients with schizophrenia in Iran: A comparative study of the clinical outcomes of mental health workers and consumers' family members as case managers. Community Ment Health J 2009;45:447-452
36. Malakouti SK, Panaghi L, Foroughan M, Salehi M, Zandi T. Farsi version of the Neuropsychiatric Inventory: Validity and reliability study among Iranian elderly with dementia. Int Psychogeriatr 2012;24:223-230
37. Khazaie H, Tahmasian M, Younesi G, et al. Evaluation of dream content among patients with schizophrenia, their siblings, patients with psychiatric diagnoses other than schizophrenia, and healthy control. Iran J Psychiatry 2012;7:26-30
38. Kay SR, Flszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull 1987;13:261
39. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988;23:99-110
40. Ghassemzadeh H, Mojtabai R, Karamghadiri N, Ebrahimkhani N. Psychometric properties of a Persian-language version of the Beck Depression Inventory-Second edition: BDI-II-PERSIAN. Depress Anxiety 2005;21:185-192 (Pubitemid 41170388)
41. Beck AT, Steer RA, Brown GK. Manual for the Beck depression inventory-II. San Antonio, TX: Psychological Corporation. 1996;1:82
42. Muehlenkamp JJ, Gutierrez PM, Osman A, Barrios FX. Validation of the Positive and Negative Suicide Ideation (PANSI) Inventory in a diverse sample of young adults. J Clin Psychol 2005;61:431-345
43. Farrahi Moghaddam J, Nakhaee N, Sheibani V, Garrusi B, Amirkafi A. Reliability and validity of the Persian version of the Pittsburgh Sleep Quality Index (PSQI-P). Sleep Breath 2012;16:79-82
44. Wibbeler T, Reichelt D, Husstedt IW, Evers S. Sleepiness and sleep quality in patients with HIV infection. J Psychosom Res 2012;72:439-442
45. Hedayati-Moghaddam M, Mashhadi IE, Zibaee R, Hosseinpoor A, Fathi-Moghaddam F, Bidkhori H. Assessment of psychiatric symptoms using SCL-90-R among HIV/AIDS individuals in Razavi Khorasan Province, Iran. Iran Red Crescent Med J 2011;13:58-59
46. Mirzai R. Standardizing and validating of SCL-90-R in Iran. Arch Iran Med 2009;12:9
47. Derogatis L. Symptoms checklist-90: Administration, scoring and procedures manual for the revised version. Baltimore, Md: Clin Psychomet Res 1977:2
48. Morlese JF, Qazi NA, Gazzard BG, Nelson MR. Nevirapineinduced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors? AIDS 2002;16:1840-1841
49. Edelman EJ, Gordon K, Rodriguez-Barradas MC, Justice AC; Vacs Project Team. Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir. AIDS Patient Care STDS 2012 26:312-319
50. Akhondzadeh S, Mohammadi M, Amini-Nooshabadi H, Davari-Ashtiani R. Cyproheptadine in treatment of chronic schizophrenia: A double-blind, placebo-controlled study. J Clin Pharm Ther 2001;24:49-52
51. Pangalila-Ratu Langi E, Jansen A. Ritanserin in the treatment of generalized anxiety disorders: A placebo-controlled trial. Hum Psychopharmacol 1988;3:6
52. Greenway SE, Pack AT, Greenway FL. Treatment of depression with cyproheptadine. Pharmacotherapy 1995;15:357-360
53. Gupta S, Popli A, Bathurst E, Hennig L, Droney T, Keller P. Efficacy of Cyproheptadine for nightmares associated with posttraumatic stress disorder. Compr Psychiatry 1998;39: 160-164 (Pubitemid 28223925)
54. Silver H, Blacker M,Weller MP, Lerer B. Treatment of chronic schizophrenia with cyproheptadine. Biol Psychiatry1989; 25:502-504 (Pubitemid 19063800)
55. Arendt G, de Nocker D, von Giesen HJ, Nolting T. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf 2007;6:147-154 (Pubitemid 46380808)
56. Sapkota S, Shakya R, Pandey B. Study on highly active antiretroviral therapy: Prescription pattern and side effects. JNPA 2012;26:12-18
57. Stiel JN, Liddle GW, Lacy WW. Studies of mechanism of cyproheptadine-induced weight gain in human subjects. Metabolism 1970;19:192-200
58. Homnick DN, Homnick BD, Reeves AJ, Marks JH, Pimentel RS, Bonnema SK. Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatr Pulmonol 2004;38: 129-134 (Pubitemid 38989733)
59. Epifanio M, Marostica PC, Mattiello R, et al. Ensaio clínico randomizado, duplo-cego e controlado por placebo de ciproheptadina para estímulo do apetite na fibrose cística; (A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis). J Pediatria 2012;88:155-160
60. Rerksuppaphol S. Effect of cyproheptadine on weight gain in malnourished children: A randomized, controlled trial. Asian Biomed 2011;4:977-982
61. Etminani-Esfahani M, Khalili H, Soleimani N, et al. Serum vitamin D concentration and potential risk factors for its deficiency in HIV positive individuals. Curr HIV Res 2012;10: 165-170
62. Khalili H, Dashti-Khavidaki S, Mohraz M, Etghani A, Almasi F. Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients. Pharmacoepidemiol Drug Saf 2009;18:848-857
63. National AIDS Committee Secretariat, Ministry of Health and Medical Education. Islamic Republic of Iran AIDS Progress Report, March 2012. Available at. http://www.unaids.org/ en/dataanalysis/knowyourresponse/ countryprogressreports/ 2012countries/ IRIran%20AIDS%20Progress%20Report%%20English%20final1-1.pdf. Accessed December 27, 2012